Keywords
quality of life
How to Cite
Abstract
Hypertension is a challenge for contemporary medicine. Available epidemiological data clearly show that many hypertensive patients in Poland and worldwide have poorly controlled hypertension, despite receiving pharmaceutical treatment. Chronic illness, including hypertension, affects the patient’s quality of life. In the last two decades, there has been increasing interest in quality of life, which has become a significant indicator in treatment effectiveness evaluation. The key aspect in quality of life is the patient’s wellbeing, in the broad sense, which affects their perception of their own health in the physical, psychological, and social domain, as well as their compliance with treatment. Effective hypotensive treatment is a prerequisite for adequate blood pressure control, reduced cardiovascular risk and high overall quality of life.References
Tykarski A, Posadzy-Małaczyńska A, Wyrzykowski B. Rozpowszechnienie nadciśnienia tętniczego oraz skuteczność jego leczenia u dorosłych mieszkańców naszego kraju. Wyniki programu WOBASZ. Kardiol Pol 2005; 63(supl. 4): 1–6.
Zdrojewski T, Szpakowski P, Bandosz P, et al. Arterial hypertension in Poland in 2002. J Hum Hypertens 2004; 18: 557–562.
Roca-Cusachs A, Dalfo A, Badia X, et al. Relation between clinical and therapeutic variables and quality of life in hypertension. J Hypertens 2001; 19: 1913–1919.
Mena-Martin FJ, Martin-Escudero JC, Simal-Blanco F, et al. Healthrelated quality of life of subjects with known and unknown hypertension: results from the population-based Hortega study. J Hypertens 2003; 21: 1283–1289.
Trzebiatowski J. Jakość życia w perspektywie nauk społecznych i medycznych – systematyzacja ujęć definicyjnych. Hygeia Public Health 2011; 46(1): 25–31.
Dziurowicz-Kozłowska A. Wokół pojęcia jakości życia. Psych Jakości Życia 2002; 1(2): 77–99.
Tobiasz-Adamczyk B. Wybrane elementy zdrowia i choroby. Kraków: Wydawnictwo Uniwersytetu Jagiellońskiego; 2000: 233–251.
Koblik T, Sieradzki J, Skrzekowska-Baran I. Ocena jakości życia i satysfakcji z leczenia pacjentów z rozpoznaniem cukrzycy leczona insulią aspart oraz dwufazową insuliną aspart w stosunku 30/70 w porównaniu z terapią insuliną ludzką. Diabetol Prakt 2008; 9: 121–131.
de Walden-Gałuszko K, Majkowicz M. Jakość życia – rozważania ogólne. Gdańsk: Wydawnictwo Uniwersytetu Gdańskiego; 1994: 13–38.
Klocek M. Badanie jakości życia w chorobach układu sercowo-naczyniowego. Nadciśn Tętn 1998; 3: 176–184.
Wiklund IK. Hypertension. In: Spilker B, ed. Quality of Life and pharmacoeconomics in clinical trials. Philadelphia: Lippincott-Raven Publishers; 1996: 893–902.
Klocek M, Kawecka-Jaszcz K. Walsartan – skuteczność przeciwnadciśnieniowa, tolerancja i wpływ na ja kość życia. Nadciśn Tętn 2005; 9: 415–424.
Bardage C, Isacson DG. Hyperten sion and health-related quality of life. An epidemiological study in Sweden. J Clin Epidemiol 2001; 54: 172–181.
Raskeliene V, Babarskiene MR, Macijauskiene J, et al. Impact of dura tion and treatment of arterial hyperten sion on health-related quality of life. Medicina (Kaunas) 2009; 45: 405–411.
Kwaśniewska M, Drygas W. Jakość życia u osób obciążonych czynnika mi ryzyka choroby niedokrwiennej ser ca. Prz Lek 2005; 62: 863–870.
Battersby C, Hartlery K, Fletcher AE, et al. Quality of life in treated hypertension: a case-control community based study. J Hum Hypertens 1995; 9: 854–859.
Klocek M, Kawecka-Jaszcz K. Jakość życia chorych z pierwotnym nadciśnie niem tętniczym. Część I. Wpływ czyn ników socjodemograficznych. Prz Lek 2003; 60: 92–100.
Laumann EO, Paik A, Rosen RC. Sexual dysfunction in the United Sta tes: prevalence and predictors. JAMA 1999; 281: 537–544.
Fogari R, Zoppi A. Effect of antihy pertensive agents on quality of life in the elderly. Drugs Aging 2004; 21: 377–393.
Weir MR. Incidence of pedal edema formation with dihydropyridine calcium channel blockers: issues and practical significance. J Clin Hypertens (Gre enwich) 2003; 5: 330–335.
Nunes MI. The relationship between quality of life and adherence to treat ment. Curr Hypertens Rep 2001; 3: 462–465.
Weir MR, Flack JM, Applegate WA. Tolerability, safety, and quality of life and hypertensive therapy: the case for low dose diuretics. Am J Med 1996; 101(Suppl. 3A): 83–92.
Fletcher AE, Chester PC, Hawkins CM, et al. The effect of verapamil and pro pranolol on quality of life in hyperten sion. J Hum Hypertens 1989; 3: 125–130.
Klocek M, Czarnecka D. Wpływ amlodypiny i enalaprylu na jakość życia cho rych z pierwotnym nadciśnieniem tętni czym. Nadciśn Tętn 2001; 1: 1–8.
Tzourio C, Anderson C, Chapman N, et al. Effects of blood pressure lowe ring with perindopril and indapamide therapy on dementia and cognitive decline in patients with cerebrovascu lar disease. Arch Intern Med 2003; 163: 1069–1075.
Coelho R, Santos A, Ribeiro L, et al. Differences in behavior profile betwe en normotensive subjects and patients with white-coat and sustained hyper tension. J Psychosom Res 1999; 46: 15–27.
Li W, Liu L, Puente JG, et al. Hy pertension and health-related quality of life: an epidemiological study in pa tients attending hospital clinics in Chi na. J Hypertens 2005; 23: 1667–1676.
Roca-Cusachs A, Dalfo A, Badia X, et al. Relation between clinical and therapeutic variables and quality of life in hypertension. J Hypertens 2001; 19: 1913–1919.
Boissel JP, Collet JP, Lion L, et al. A randomized comparison of the effect of four antihypertensive monotherapies on the subjective quality of life in previously untreated asymptomatic patients: field trial in general practice. The OCAPI Study Group. J Hypertens 1995; 13: 1059–1067.
Wiklund IK, Halling K, Ryden-Bergsten T, et al. Does lowering the blood pressure improve the mood? Quality of life results from the Hypertension Optimal Treatment (HOT) Study. Blood Press 1997; 6: 357–364.
Zygmuntowicz M, Olszanecka-Glinianowicz M, Chudek J. Jakość życia osób z nadciśnieniem tętniczym. Endokrynol Otyłość 2011; 7(3): 179–185.